XML 23 R10.htm IDEA: XBRL DOCUMENT
v3.21.2

EARNINGS PER SHARE | 6 Months Ended
--- | ---
Jun. 30, 2021
Earnings Per Share, Basic and Diluted [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Amounts attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |
Net income attributable to Quest Diagnostics | $ | 631 |  |  | $ | 185 |  |  | $ | 1,100 |  |  | $ | 284 |
Less: Earnings allocated to participating securities | 3 |  |  | 1 |  |  | 4 |  |  | 1 |
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted | $ | 628 |  |  | $ | 184 |  |  | $ | 1,096 |  |  | $ | 283 |
Weighted average common shares outstanding – basic | 125 |  |  | 134 |  |  | 129 |  |  | 134 |
Effect of dilutive securities: |  |  |  |  |  |  |
Stock options and performance share units | 2 |  |  | 2 |  |  | 2 |  |  | 1 |
Weighted average common shares outstanding – diluted | 127 |  |  | 136 |  |  | 131 |  |  | 135 |
Earnings per share attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |
Basic | $ | 5.05 |  |  | $ | 1.38 |  |  | $ | 8.52 |  |  | $ | 2.12 |
Diluted | $ | 4.96 |  |  | $ | 1.36 |  |  | $ | 8.38 |  |  | $ | 2.09 |
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Stock options and performance share units | 1 |  |  | 1 |  |  | 1 |  |  | 2 |
In April 2021, the Company entered into ASRs with several financial institutions to repurchase $1.5 billion of the Company's common stock as part of the Company's share repurchase program. See Note 9 for further details. The sum of basic and diluted earnings per share attributable to Quest Diagnostics' common stockholders for the first two quarters of 2021 did not equal the total for the six months ended June 30, 2021 due to both quarterly fluctuations in the Company's earnings and in the weighted average common shares outstanding throughout the period as a result of the impact of the ASRs.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareBasicAndDilutedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration